Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2024, Quick Ratio deteriorated to 0 a new company low.

Within Major Pharmaceutical Preparations industry 498 other companies have achieved higher Quick Ratio than Orgenesis Inc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 4589 to 4859.

Explain Quick Ratio?
How much Cash & cash equivalents ORGS�s has?
What are ORGS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ORGS Quick Ratio	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4
Y / Y Current Liabilities Change	64.08 %	152.06 %	149.39 %	108.29 %	16.2 %
Y / Y Cash & cash equivalent Change	-90.68 %	270.91 %	-57.22 %	-97.01 %	-84.24 %
Quick Ratio MRQ	0	0.01	0	0	0.05
ORGS's Total Ranking	# 4859	# 4589	# 4205	# 5760	# 5059
Seq. Current Liabilities Change	-25.32 %	13.72 %	9.19 %	76.94 %	14.72 %
Seq. Cash & cash equivalent Change	-61.76 %	164.94 %	-3.75 %	-90.44 %	1421.82 %

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 499
Healthcare Sector	# 1018
Overall Market	# 4859

Quick Ratio Statistics
High	Average	Low
7.18	0.74	0
(Sep 30 2020)		(Jun 30 2024)

Financial Statements
Orgenesis Inc 's Current Liabilities	$ 27 Millions	Visit ORGS's Balance sheet
Orgenesis Inc 's Cash & cash equivalent	$ 0 Millions	Visit ORGS's Balance sheet
Source of ORGS's Sales		Visit ORGS's Sales by Geography

Cumulative Orgenesis Inc 's Quick Ratio

ORGS's Quick Ratio for the trailling 12 Months

ORGS Quick Ratio	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	115.66 %	105.53 %	22.02 %	-7.67 %	-28.11 %
Y / Y Cash & cash equivalent TTM Growth	-88.28 %	-85.43 %	-90.62 %	-91.34 %	-68.12 %
Quick Ratio TTM	0	0.01	0.01	0.02	0.07
Total Ranking TTM	# 3819	# 3650	# 3510	# 3650	# 4594
Seq. Current Liabilities TTM Growth	9.29 %	23.78 %	26.21 %	26.31 %	4.15 %
Seq. Cash & cash equivalent TTM Growth	-63.36 %	14.2 %	-8.94 %	-69.25 %	-54.43 %

Quick ratio ranking by company, industry and sector >> Back to ORGS Financial Strength Comparisons >> Go to Compare ORGS Quick Ratio to its Competitors

On the trailing twelve months basis Due to cut in Current Liabilities in the Q4 2024 to $26.92 millions, cumulative Quick Ratio decreased to 0 below the Orgenesis Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Quick Ratio than Orgenesis Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 3650 to 3819.

Explain Quick Ratio?
How much Cash & cash equivalents ORGS�s has?
What are ORGS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 465
Healthcare Sector	# 962
Within the Market	# 3819

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.55	0.9	0
(Sep 30 2020)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2024 MRQ Cash & cash equivalent	Dec 31 2024 MRQ Current Liabilities
Gridai Technologies Corp	0.01	$ 0.163 Millions	$ 27.546 Millions
Neonc Technologies Holdings Inc	0.01	$ 0.090 Millions	$ 15.377 Millions
Propanc Biopharma Inc	0.01	$ 0.021 Millions	$ 3.793 Millions
Oncotelic Therapeutics Inc	0.00	$ 0.086 Millions	$ 19.200 Millions
Novo Nordisk A	0.00	$ 395.997 Millions	$ 97,239.113 Millions
Regen Biopharma Inc	0.00	$ 0.018 Millions	$ 5.379 Millions
Nexien Biopharma Inc	0.00	$ 0.001 Millions	$ 0.424 Millions
Orgenesis Inc	0.00	$ 0.078 Millions	$ 26.920 Millions
Skinvisible Inc	0.00	$ 0.010 Millions	$ 3.680 Millions
Bioxytran Inc	0.00	$ 0.005 Millions	$ 2.543 Millions
Semnur Pharmaceuticals Inc	0.00	$ 0.003 Millions	$ 1.556 Millions
Accustem Sciences Inc	0.00	$ 0.005 Millions	$ 3.364 Millions
Bioadaptives Inc	0.00	$ 0.003 Millions	$ 1.726 Millions
Aeon Biopharma inc	0.00	$ 0.013 Millions	$ 14.149 Millions

Date modified: 2026-06-22T14:32:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.